LDLR and central nervous system cancer: As previously reported, Pep-22 has dual-targeting bioactivity for both BBB and glioma cells by binding to LDLR [64], and c(RGDfK) exhibits dual-targeting capabilities toward the BBTB and glioma cells by binding to integrins αvβ3/αvβ5[113].